Mirum Pharmaceuticals ((MIRM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mirum Pharmaceuticals is conducting a clinical study titled ‘A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis.’ The study aims to assess the effectiveness of volixibat, an investigational drug, in alleviating itching associated with Primary Sclerosing Cholangitis (PSC) and its potential impact on disease progression.
The intervention being tested is volixibat, an oral drug administered as an Ileal Bile Acid Transporter (IBAT) inhibitor. It is designed to reduce itching in PSC patients by inhibiting bile acid transport.
This Phase 2 study is interventional, with participants randomly assigned to different groups. It follows a parallel intervention model and employs double masking, meaning both participants and investigators are unaware of group assignments. The primary aim is treatment-focused.
The study began on December 18, 2020, with primary completion anticipated in the future. The latest update was submitted on August 19, 2025, indicating ongoing recruitment and progress.
For investors, this study update could influence Mirum Pharmaceuticals’ stock performance positively, as successful outcomes may enhance market confidence. In the competitive landscape, advancements in PSC treatment could position Mirum favorably against peers.
The study is ongoing, with further details accessible on the ClinicalTrials portal.